Press Release

Illumina Launches the NeoPrep Library Prep System

Innovative Load-and-Go System Brings High-Quality, Reproducible Library Prep to Any Lab

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2015-- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the NeoPrep™ Library Prep System, which greatly simplifies library preparation and delivers high-quality sequencing-ready libraries for next-generation sequencing (NGS). The newest addition to the Illumina portfolio of NGS solutions consists of a NeoPrep desktop instrument, disposable library cards, and reagents. Together with Illumina sequencers and the BaseSpace® computing environment, the new system plays an integral role in providing NGS users with the easiest, most efficient and complete workflow.

NeoPrep Library Prep System (Photo: Business Wire)

NeoPrep Library Prep System (Photo: Business Wire)

The NeoPrep System is the first commercially available product that performs library prep, quantification and normalization, in a single, self-contained instrument. Innovative digital microfluidics technology decreases hands-on time from several hours to 30 minutes. By precisely manipulating droplets within the tightly controlled library card environment, the system delivers reliable, high-quality DNA and RNA libraries from starting amounts 4 to 10 times lower than those required for equivalent manual assays. By creating 16 libraries per run, users can prepare up to 160 libraries per week, providing an affordable, walk-away solution that simplifies lab processes, and reduces the need for ancillary equipment and user-supplied reagents and consumables.

“Illumina is enabling the broadest-possible adoption of NGS across research, clinical, and applied markets,” said Kirk Malloy, Senior Vice President and General Manager of Illumina’s Life Science Business. “The NeoPrep System is a key milestone in the evolution of NGS technology. It makes NGS accessible to any lab by radically simplifying the library preparation process, creating a seamless workflow of Illumina solutions for library preparation, sequencing, and data analysis. By continuing to drive adoption of NGS, we aim to help our customers generate new discoveries and applications in oncology, reproductive health, forensics, microbiology, and other key markets.”

The NeoPrep System is designed for use with the Illumina portfolio of library preparation kits, supporting the most commonly used NGS applications on all Illumina sequencing systems. Each kit includes the library card as well as all reagents required to create NeoPrep libraries.

The NeoPrep System and NeoPrep versions of the TruSeq® Nano DNA Kit and TruSeq Stranded mRNA Kit will begin shipping in March 2015. Additional library preparation products will become available later in the year, including NeoPrep versions of the TruSeq DNA PCR-Free Kit and other targeted resequencing kits.

For more information, please visit

About Illumina

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit and follow @illumina.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Rebecca Chambers
Jennifer Temple

Recent Articles

How the UK is setting new standards for genomic research and better health care
How the UK is setting new standards for genomic research and better health care
Merging discovery with clinical care at Ontario Institute for Cancer Research
Video: Merging discovery with clinical care at Ontario Institute for Cancer Research
Preventing postoperative infections one NGS assay at a time
Preventing postoperative infections one NGS assay at a time